Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Biopharma's record venture year ends with a slowdown
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Another strong quarter from the venture world
Private biotechs received almost $4bn in venture financing in the third quarter, as the healthy financing climate showed few signs of deteriorating.
$100m venture rounds become standard for device makers
The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.
The venture money keeps flowing for biopharma
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.
Another venture funding surge sets up a strong 2018
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
2017 rewrites the record books as venture funding accelerates
In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.
Medtech funding ventures into the unknown
In a truly extraordinary year, the top 10 venture rounds made up more than half of the total invested.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.